Canaccord Genuity Reiterates Buy on Biodesix, Maintains $3.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson has reiterated a Buy rating on Biodesix (NASDAQ:BDSX) and maintained a price target of $3.5.
December 07, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Kyle Mikson has reiterated a Buy rating on Biodesix and maintained a price target of $3.5.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst like Kyle Mikson can instill confidence in investors and potentially lead to a positive short term impact on Biodesix's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100